FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics director Jacob A. Frenkel received a grant of 200,000 shares of Common Stock in the form of restricted stock units. The award was made at a stated price of $0.00 per share as stock-based compensation, rather than an open-market purchase.
According to the grant terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six-month anniversary of that date, if he remains employed by the company. After this award, Frenkel directly holds 243,777 shares of the company’s stock.
ARBEL IRIT reported acquisition or exercise transactions in this Form 4 filing.
Brainstorm Cell Therapeutics director Irit Arbel received an equity award of 120,000 shares of Common Stock in the form of restricted stock units. The grant was made on February 26, 2026 at a stated price of $0.00 per share, indicating it is compensation rather than an open-market purchase.
The RSUs were awarded under the company’s 2014 Global Share Option Plan. According to the terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six‑month anniversary of the grant date, as long as Arbel remains employed by the company through each vesting date. After this award, Arbel’s reported direct holdings total 161,054 shares of Common Stock.
Brainstorm Cell Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Peter Pitts as a director effective May 25, 2026, to serve until the company’s 2026 Annual Meeting of Stockholders and until his successor is elected and qualified.
Pitts, age 67, brings over 30 years of health care public policy experience, including prior service as Associate Commissioner of the U.S. Food & Drug Administration and President of the Center for Medicine in the Public Interest. Upon appointment, he received an option to purchase up to 150,000 shares of common stock, with half vesting immediately and half on the six-month anniversary of issuance. The Board determined he is independent under applicable SEC rules, and the company plans to enter into a standard director indemnification agreement with him.
Bairu Menghisteab reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Menghisteab Bairu received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. These options, granted under the company’s 2014 Stock Incentive Plan, expire on February 26, 2036.
The award vests over a short schedule: 50% of the options vest on the grant date and the remaining 50% vest on the six-month anniversary, as long as Bairu remains employed by the company through each vesting date. Following this grant, Bairu holds 150,000 stock options directly.
BrainStorm Cell Therapeutics director Anthony J. Polverino received a grant of stock options to acquire 150,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and are a form of equity compensation.
The options vest in two equal parts: 50% vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant, provided he remains employed through each vesting date. All 150,000 options are scheduled to expire on February 26, 2036, giving a long-dated incentive tied to the company’s share performance.
HARTOUNIAN HARTOUN reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Hartoun Hartoun received a grant of stock options to buy 225,000 shares of common stock at $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and expire on February 26, 2036.
The award vests over a short period: 50% of the options vest on the grant date and the remaining 50% vest on the six‑month anniversary, as long as Hartoun remains employed through each vesting date. After this grant, he holds 225,000 stock options directly.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Stacy Lindborg received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. All 150,000 options were outstanding after the grant.
The options were granted under the company’s 2014 Stock Incentive Plan. According to the terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, provided she remains employed through each vesting date. The options expire on February 26, 2036, giving a long-dated incentive tied to the company’s future share performance.
BrainStorm Cell Therapeutics director Naor Nir received a new stock option grant. He was awarded options to buy 180,000 shares of common stock at an exercise price of $0.70 per share under the company’s 2014 Stock Incentive Plan.
According to the vesting terms, 50% of the options vest on the grant date, and the remaining 50% vest on the six‑month anniversary of the grant date, provided he remains employed by the company through each vesting date. Following this award, he holds options covering 180,000 shares from this grant, which expire on February 26, 2036.
BRAINSTORM CELL THERAPEUTICS INC. director Ibrahim B. Dagher received a grant of stock options to acquire 225,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan as equity-based compensation.
According to the vesting terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, as long as Dagher remains employed by the company through each vesting date. Following this grant, his reported holdings in this option series total 225,000 options, which are scheduled to expire on February 26, 2036.
Brainstorm Cell Therapeutics Inc. is registering up to 7,796,496 shares of common stock for resale by existing investors. This includes 1,310,528 outstanding shares, up to 2,233,334 shares issuable on exercise of pre-funded warrants, and up to 4,252,634 shares issuable on exercise of common stock purchase warrants.
The company will not receive proceeds from investor resales, but would receive cash if warrants are exercised, at prices of $0.0005, $1.00, or $1.45 per share. Brainstorm trades on the OTCQB under “BCLI,” last quoted at $0.716 per share, and remains a smaller reporting, pre-revenue biotech focused on its NurOwn cell therapy for ALS and other neurodegenerative diseases, with a history of losses and going-concern risk highlighted among extensive risk factors.